Abstract
The concentration of low-density lipoprotein cholesterol has long been generally accepted as one of the strongest, independent risk factors for the development of cardiovascular disease. However, an increasing number of studies suggest that the ratio of apolipoprotein B (apoB) to apolipoprotein A-I (apoA-I) is a better risk predictor. In the present review, we focus on apoB and apoA-I as factors in predicting vascular risk in epidemiological studies only, and not in studies involving pharmaceutical intervention. The majority of studies in the present review show that apoB and the apoB/apoA-I ratio are independently and more strongly associated with vascular risk across varying age-groups and geographic regions than are conventional lipids, lipoproteins and lipid ratios.
Keywords: Apolipoprotein B, apoB/apoA-I ratio, intima-media thickness, plaque, myocardial infarction, stroke, peripheral atherosclerosis.
Current Pharmaceutical Design
Title:Apolipoprotein B and Apolipopotein A-I in Vascular Risk Prediction-A Review
Volume: 20 Issue: 40
Author(s): C. Schmidt and G. Bergstrom
Affiliation:
Keywords: Apolipoprotein B, apoB/apoA-I ratio, intima-media thickness, plaque, myocardial infarction, stroke, peripheral atherosclerosis.
Abstract: The concentration of low-density lipoprotein cholesterol has long been generally accepted as one of the strongest, independent risk factors for the development of cardiovascular disease. However, an increasing number of studies suggest that the ratio of apolipoprotein B (apoB) to apolipoprotein A-I (apoA-I) is a better risk predictor. In the present review, we focus on apoB and apoA-I as factors in predicting vascular risk in epidemiological studies only, and not in studies involving pharmaceutical intervention. The majority of studies in the present review show that apoB and the apoB/apoA-I ratio are independently and more strongly associated with vascular risk across varying age-groups and geographic regions than are conventional lipids, lipoproteins and lipid ratios.
Export Options
About this article
Cite this article as:
Schmidt C. and Bergstrom G., Apolipoprotein B and Apolipopotein A-I in Vascular Risk Prediction-A Review, Current Pharmaceutical Design 2014; 20 (40) . https://dx.doi.org/10.2174/1381612820666140620121828
DOI https://dx.doi.org/10.2174/1381612820666140620121828 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statins in Aortic Stenosis
Current Pharmaceutical Design The Anti-Atherogenic Effects of Thiazolidinediones
Current Diabetes Reviews Maternal Nutrition and Predisposition to Later Kidney Disease
Current Drug Targets Comparison Between the Effects of Bupivacaine and Levobupivacaine for Spinal Anesthesia on QT Dispersion
Cardiovascular & Hematological Disorders-Drug Targets Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Recent Trends in the Design, Synthesis and Biological Exploration of β-Lactams
Current Medicinal Chemistry The Development of New Concepts for Assessing Reproductive Toxicity Applicable to Large Scale Toxicological Programmes
Current Pharmaceutical Design Fibrinolytic Therapy in Acute Stroke
Current Cardiology Reviews Beta-Blockers in Children with Congenital Heart Disease Before a Corrective Procedure
Reviews on Recent Clinical Trials Vitamin D: A Regulator of Metabolism and Inflammation
Current Nutrition & Food Science Sutureless Aortic Valve Replacement Using Perceval S Valve
Recent Patents on Cardiovascular Drug Discovery Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Gauging Reactive Metabolites in Drug-Induced Toxicity
Current Medicinal Chemistry New Achievements in Bioinformatics Prediction of Post Translational Modification of Proteins
Current Topics in Medicinal Chemistry Fatty Acids Recommendations: Controversies and Updates
Current Nutrition & Food Science Cardiac Biomarkers in the Identification of Future Risk in Chronic Obstructive Pulmonary Disease
Current Topics in Medicinal Chemistry Malondialdehyde and Superoxide Dismutase in High-dose Calcium Supplemented Women in Relation to Iron and Calcium Panels
Current Nutrition & Food Science Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry